![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter
Effects of Treatment of Malignant Lymphomas on the Granulocytic Progenitor Cells (CFUc)
Study of the after-effects of therapy on the healthy organs is one of the main preoccupations of oncology. Although progress in therapeutics has clearly improved the prognosis for malignant lymphomas, the afte...
-
Chapter
First Results of a Randomized Trial on Immunotherapy of Head and Neck Tumors
Trials of active nonspecific immunotherapy as adjuvant therapy for tumors have increased dramatically in number since the results that have been published on acute leukemia [6] and melanoma [3, 5, 7–9]. In spi...
-
Chapter and Conference Paper
High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors
Despite progress in the treatment of disseminated non-seminomatous germ cell tumors (NSGCT), 20–30%of patients do not achieve CR or relapse [1]. We evaluated high-dose chemotherapy (HDC) followed by autologous...
-
Article
Phase II trial of pirarubicin in the treatment of advanced bladder cancer
Doxorubicin is one of the standard drugs in the chemotherapy of advanced urothelial tumors. Pirarubicin, a new anthracycline, turned out to be equally active and less toxic than its parent compound in preclini...
-
Chapter and Conference Paper
No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors
The results of the treatment of non-seminomatous germ cell tumors (NSGCT) have been dramatically improved by Cisplatin-based chemotherapy regimens and selective indication of surgery. Approximately 80 % of all...
-
Article
Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer
Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor m...
-
Article
Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer
Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor mo...
-
Chapter
Testicular tumors
Tumors of the testicles, although relatively infrequent (less than 1% of cancers in males), are still used as a model for study in oncology, principally as a result of their curability by chemotherapy.
-
Article
Open AccessPrognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
Our purpose was to determine, in patients with metastatic colorectal carcinoma treated with irinotecan single-agent after 5-FU failure, the most significant predictive parameters for tumour response, progressi...
-
Article
Open AccessA phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered on four consecutive courses with peripheral blood progenitor cell and granulocyte-colo...
-
Article
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
Objective: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy...
-
Article
Open AccessThe risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area
The aim of this study was to evaluate the risk of thrombo-embolic events (TEE) in patients with germ-cell tumours (GCT) who receive cisplatin-based chemotherapy, to compare this risk to that of a matched contr...
-
Chapter
Traitement des formes de mauvais pronostic
-
Article
Réflexions sur l’organisation de l’oncogériatrie et rôle des réseaux
Le réseau d’oncogériatrie devra comprendre toutes les personnes et toutes les structures qui gèrent la prise en charge clinique de la personne âgée atteinte de cancer à toutes les étapes de la maladie. Les out...
-
Article
Quelle évaluation gérontologique faut-il utiliser pour les essais multicentriques?
Peu de personnes âgées atteintes de cancer sont incluses dans des essais cliniques. Ainsi, la connaissance sur l’efficacité et la tolérance des traitements est-elle médiocre dans cette population de patients. ...
-
Chapter
Cancer de la vessie/uretère
Les tumeurs urothéliales sont des tumeurs fréquentes qui se développent aux dépens de l’arbre urinaire. Elles siègent le plus souvent dans la vessie mais elles peuvent aussi avoir comme origine le haut apparei...